These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 14630675)

  • 1. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response.
    Pace A; Vidiri A; Galiè E; Carosi M; Telera S; Cianciulli AM; Canalini P; Giannarelli D; Jandolo B; Carapella CM
    Ann Oncol; 2003 Dec; 14(12):1722-6. PubMed ID: 14630675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas.
    Brada M; Viviers L; Abson C; Hines F; Britton J; Ashley S; Sardell S; Traish D; Gonsalves A; Wilkins P; Westbury C
    Ann Oncol; 2003 Dec; 14(12):1715-21. PubMed ID: 14630674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide.
    Koekkoek JA; Dirven L; Heimans JJ; Postma TJ; Vos MJ; Reijneveld JC; Taphoorn MJ
    J Neurooncol; 2016 Jan; 126(2):347-54. PubMed ID: 26547911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide.
    Koekkoek JA; Dirven L; Heimans JJ; Postma TJ; Vos MJ; Reijneveld JC; Taphoorn MJ
    J Neurol Neurosurg Psychiatry; 2015 Apr; 86(4):366-73. PubMed ID: 25055819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temozolomide low-dose chemotherapy in newly diagnosed low-grade gliomas: activity, safety, and long-term follow-up.
    Villani V; Merola R; Vidiri A; Fabi A; Carosi M; Giannarelli D; Marucci L; Maschio M; Carapella CM; Pace A
    Tumori; 2017 May; 103(3):255-260. PubMed ID: 27716874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients.
    Silvani A; Eoli M; Salmaggi A; Lamperti E; Maccagnano E; Broggi G; Boiardi A
    J Neurooncol; 2004 Jan; 66(1-2):203-8. PubMed ID: 15015788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgery, radiotherapy and temozolomide in treating high-grade gliomas.
    Parlato C; Barbarisi M; Moraci M; Moraci A
    Front Biosci; 2006 May; 11():1280-3. PubMed ID: 16368514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temozolomide after radiotherapy in recurrent "low grade" diffuse brainstem glioma in adults.
    Reyes-Botero G; Laigle-Donadey F; Mokhtari K; Martin-Duverneuil N; Delattre JY
    J Neurooncol; 2014 Dec; 120(3):581-6. PubMed ID: 25139026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study.
    Brandes AA; Ermani M; Basso U; Amistà P; Berti F; Scienza R; Rotilio A; Pinna G; Gardiman M; Monfardini S
    Ann Oncol; 2001 Feb; 12(2):255-7. PubMed ID: 11300334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
    Parasramka S; Talari G; Rosenfeld M; Guo J; Villano JL
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011773. PubMed ID: 28744879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.
    Chang SM; Prados MD; Yung WK; Fine H; Junck L; Greenberg H; Robins HI; Mehta M; Fink KL; Jaeckle KA; Kuhn J; Hess K; Schold C
    Cancer; 2004 Apr; 100(8):1712-6. PubMed ID: 15073861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.
    Izquierdo C; Alentorn A; Idbaih A; Simó M; Kaloshi G; Ricard D; Barritault M; Meyronet D; Bruna J; Honnorat J; Delattre JY; Ducray F
    J Neurooncol; 2018 Feb; 136(3):533-539. PubMed ID: 29143276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas.
    Roelcke U; Wyss MT; Nowosielski M; Rudà R; Roth P; Hofer S; Galldiks N; Crippa F; Weller M; Soffietti R
    Neuro Oncol; 2016 May; 18(5):744-51. PubMed ID: 26578622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rechallenge temozolomide in glioma: A case series from India.
    Patil VM; Tonse R; Kothari R; Chandrasekaran A; Pande N; Epari S; Gupta T; Jalali R
    Indian J Cancer; 2017; 54(1):368-371. PubMed ID: 29199725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. When temozolomide alone fails: adding procarbazine in salvage therapy of glioma.
    Huang F; Kavan P; Guiot MC; Markovic Y; Roberge D
    Can J Neurol Sci; 2008 May; 35(2):192-7. PubMed ID: 18574933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life in low-grade glioma patients receiving temozolomide.
    Liu R; Solheim K; Polley MY; Lamborn KR; Page M; Fedoroff A; Rabbitt J; Butowski N; Prados M; Chang SM
    Neuro Oncol; 2009 Feb; 11(1):59-68. PubMed ID: 18713953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temozolomide in children with progressive low-grade glioma.
    Gururangan S; Fisher MJ; Allen JC; Herndon JE; Quinn JA; Reardon DA; Vredenburgh JJ; Desjardins A; Phillips PC; Watral MA; Krauser JM; Friedman AH; Friedman HS
    Neuro Oncol; 2007 Apr; 9(2):161-8. PubMed ID: 17347491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach.
    Perry JR; Rizek P; Cashman R; Morrison M; Morrison T
    Cancer; 2008 Oct; 113(8):2152-7. PubMed ID: 18756530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma.
    Verhoeff JJC; Lavini C; van Linde ME; Stalpers LJA; Majoie CBLM; Reijneveld JC; van Furth WR; Richel DJ
    Ann Oncol; 2010 Aug; 21(8):1723-1727. PubMed ID: 20064829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.